For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is AngioDynamics (ANGO) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.AngioDynamics is a member of the Medical sector. This group includes 1003 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zac ...

Group 1 - The core viewpoint is that AngioDynamics (ANGO) has significant upside potential, with a mean price target of $15.33 indicating a 68.3% increase from its current price of $9.11 [1] - Analysts have set short-term price targets ranging from $15 to $16, with the lowest estimate suggesting a 64.7% increase and the highest indicating a 75.6% upside, alongside a standard deviation of $0.58, reflecting a consensus among analysts [2] - There is a strong agreement among analysts regarding improved earnings estimates for ANGO, which historically correlates with positive stock price movements [4][10] Group 2 - The Zacks Consensus Estimate for ANGO's current year earnings has increased by 10.8% over the last 30 days, with no negative revisions, indicating positive sentiment [11] - ANGO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for near-term upside [12]

Core Viewpoint - AngioDynamics, Inc. reported better-than-expected results for the third quarter of fiscal 2025, with adjusted earnings per share (EPS) of 3 cents, compared to a loss of 16 cents in the same quarter last year and a consensus estimate of a loss of 13 cents [1][18]. Financial Performance - Adjusted loss per share on a pro-forma basis was 8 cents, improved from 16 cents year-over-year [2]. - GAAP loss per share was 11 cents, significantly better than the loss of $4.67 reported in the prior year [2][3]. - Total revenues for the fiscal third quarter were $72 million, down 4.2% year-over-year but exceeding the Zacks Consensus Estimate by 2% [4]. - On a pro forma basis, net sales were $72 million, reflecting a 9.2% increase year-over-year [4]. Revenue Breakdown - U.S. net revenues were $61.3 million, down 1.6% year-over-year, but up 9.9% on a pro forma basis [6]. - International revenues totaled $10.7 million, down 16.9% year-over-year on a reported basis, but up 5.1% on a pro forma basis [7]. Segment Analysis - Med Tech revenues were $31.3 million, up 21.3% year-over-year, surpassing projections [8][9]. - Med Device revenues were $40.7 million, down 17.6% from the previous year, but up 0.9% on a pro forma basis [11]. Margin and Expense Analysis - Pro forma gross profit increased by 15.4% year-over-year to $38.9 million, with gross margin expanding by 290 basis points to 54% [12]. - Sales and marketing expenses rose by 7.9% to $25.5 million, while R&D expenses decreased by 14.4% to $6.9 million [13]. Cash Position - The company ended the quarter with cash and cash equivalents of $44.8 million, down from $54.1 million in the previous quarter, and had no debt [15]. Guidance - AngioDynamics revised its fiscal 2025 guidance, expecting net sales between $285 million and $288 million, indicating growth of 5.3-6.4% from the previous year [16]. - Adjusted loss per share is now projected to be between 31 cents and 34 cents, an improvement from earlier estimates [17].

Revenue and Sales Performance - Revenue decreased by 4.2% to $72.0 million for the three months ended February 28, 2025, and by 8.8% to $212.3 million for the nine months ended February 28, 2025[120]. - Med Tech segment grew by 21.3% in the third quarter, while Med Device segment declined by 17.6%[120]. - Med Tech segment net sales increased by $5.5 million and $13.8 million for the three and nine months ended February 28, 2025, respectively[125]. - The company had a sales order backlog of $0.5 million as of February 28, 2025[124]. Profitability and Loss - Gross profit increased by 630 basis points to 54.0% for the three months ended February 28, 2025[120]. - Net loss decreased by $183.3 million to $4.4 million for the three months ended February 28, 2025[120]. - Total company gross profit increased by $3.0 million for the three months ended February 28, 2025, but decreased by $0.7 million for the nine months ended February 28, 2025 compared to the same periods in 2024[129]. - Med Tech segment gross profit increased by $3.7 million and $9.0 million for the three and nine months ended February 28, 2025, respectively[131]. - Med Device segment gross profit decreased by $0.7 million and $9.7 million for the three and nine months ended February 28, 2025, respectively[131]. - The company recorded a net loss of $27.9 million for the nine months ended February 28, 2025, compared to a loss of $170.9 million for the same period in the previous year[148]. Expenses and Cost Management - Research and development expenses decreased by $1.3 million and $5.2 million for the three and nine months ended February 28, 2025, respectively[134]. - Selling and marketing expenses increased by $0.1 million for the three months ended February 28, 2025 but decreased by $1.5 million for the nine months ended February 28, 2025[137]. - General and administrative expenses decreased by $0.1 million for the three months ended February 28, 2025 but increased by $1.1 million for the nine months ended February 28, 2025[138]. - Legal expenses decreased by $23.3 million and $30.0 million, primarily due to a $19.3 million settlement with BD in the prior year[144]. Cash Flow and Financial Position - Cash used in operations decreased by $4.2 million to $28.9 million for the nine months ended February 28, 2025[125]. - Cash used in operating activities was $(28,939) thousand for the nine months ended February 28, 2025, compared to $(33,159) thousand for the nine months ended February 29, 2024[145]. - Cash provided by financing activities was $5,515 thousand for the nine months ended February 28, 2025, compared to $(59,248) thousand for the same period in the previous year[145]. - Cash and cash equivalents totaled $44.8 million as of February 28, 2025, down from $76.1 million as of May 31, 2024[143]. - The company did not have any outstanding debt as of February 28, 2025 and May 31, 2024[143]. - The company has a cash balance sufficient to meet anticipated capital needs for at least the next 12 months[147]. Strategic Initiatives - The restructuring plan is expected to generate $15.0 million in annual cost savings starting in fiscal year 2027[116]. - The company repurchased 72,141 shares for $0.5 million and 171,706 shares for $1.1 million in the first and second quarters of fiscal year 2025, respectively[117]. - The company entered into agreements to sell manufacturing facilities for a total purchase price of $6.7 million[118]. - The company achieved a sales milestone related to divested products, recording a receivable of $5.5 million expected to be paid in the fourth quarter of fiscal year 2025[144]. - The company received $100.0 million from the divestiture of the dialysis and BioSentry businesses in the first quarter of fiscal year 2024[148]. Foreign Currency and Taxation - Approximately 3.5% of the company's sales were denominated in foreign currencies for the nine months ended February 28, 2025[151]. - The effective tax rate for the three months ended February 28, 2025 was 0.0%, compared to 6.0% for the same period in 2024[141]. - Unrealized foreign currency fluctuations increased by $0.1 million and $0.3 million for the three and nine months ended February 28, 2025, respectively[144]. Working Capital - Working capital was negatively impacted by a decrease in accounts payable and accrued liabilities of $18.5 million for the period ended February 28, 2025[148].

AngioDynamics Third Quarter Fiscal Year 2025 Earnings Presentation April 2, 2025 Forward-Looking Statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunitie ...

AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2025 Earnings Conference Call April 2, 2025 8:00 AM ET Company Participants Jim Clemmer - President & CEO Stephen Trowbridge - EVP & CFO Conference Call Participants John Young - Canaccord Genuity Steven Lichtman - Oppenheimer Eduardo Martinez - H.C. Wainwright Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2025 Third Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal ...

Core Viewpoint - AngioDynamics reported quarterly earnings of $0.03 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.13 per share, marking an earnings surprise of 123.08% [1] Financial Performance - The company posted revenues of $72 million for the quarter ended February 2025, surpassing the Zacks Consensus Estimate by 2%, although this represents a decline from year-ago revenues of $75.18 million [2] - Over the last four quarters, AngioDynamics has exceeded consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - AngioDynamics shares have increased approximately 5.5% since the beginning of the year, contrasting with the S&P 500's decline of 4.2% [3] Future Outlook - The company's earnings outlook will be crucial for determining the sustainability of its stock price movement, with current consensus EPS estimates at -$0.09 for the coming quarter and -$0.37 for the current fiscal year [4][7] - The estimate revisions trend for AngioDynamics is currently mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Instruments industry, to which AngioDynamics belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Financial Performance - Pro forma net sales for Q3 FY2025 were $72.0 million, representing a 9.2% increase year-over-year[3] - Adjusted EBITDA for Q3 FY2025 was $1.3 million, compared to a loss of $3.6 million in Q3 FY2024[13] - The company recorded a GAAP net loss of $4.4 million, or a loss per share of $(0.11) in Q3 FY2025[12] - For the three months ended February 28, 2025, Angiodynamics reported a net loss of $4,407,000 compared to a net loss of $187,736,000 for the same period in 2024[35] - Adjusted net income for the three months ended February 28, 2025, was $1,167,000, while for the same period in 2024, it was a loss of $6,279,000[35] - The net loss for the three months ended February 28, 2025, was $4,407 thousand, compared to a net loss of $187,736 thousand for the same period in 2024[32] - The net loss for the nine months ended February 28, 2025, was $27,943 thousand, compared to a net loss of $170,900 thousand for the same period in 2024[34] - The company reported a basic loss per share of $0.68 for the nine months ended February 28, 2025, compared to a loss per share of $4.26 for the same period in 2024[34] Sales and Revenue - Med Tech net sales reached $31.3 million, a 22.2% increase from $25.7 million in the prior-year period[8] - The company expects FY2025 net sales to be in the range of $285 to $288 million, reflecting growth of 5.3% to 6.4% over FY2024[21] - Med Tech net sales growth guidance for FY2025 has been increased to 14% to 16% from the previous 12% to 15%[21] - Net sales for the three months ended February 28, 2025, were $72,004,000, a decrease of 4.2% compared to $75,182,000 for the same period in 2024[48] - Med Tech segment reported net sales of $31,341,000, representing a growth of 21.3% from $25,844,000 in the prior year[48] - Med Device segment experienced a decline in net sales to $40,663,000, down 17.6% from $49,338,000 year-over-year[48] - For the nine months ended February 28, 2025, net sales were $212,340 thousand, a decrease of 8.9% from $232,934 thousand for the same period in 2024[34] - The Med Tech segment's nine-month net sales were $90,863,000, reflecting a growth of 17.9% compared to $77,068,000 in the previous year[52] Profitability and Margins - Gross margin for Q3 FY2025 was 54.0%, up 290 basis points compared to Q3 FY2024[11] - Gross profit margin improved to 54.0% for the three months ended February 28, 2025, compared to 47.7% for the same period in 2024[32] - Gross profit for the Med Tech segment was $19,588,000, with a gross profit margin of 62.5%, compared to $15,857,000 and 61.4% in the previous year[50] - Total gross profit for the three months ended February 28, 2025, was $38,857,000, an increase of 8.4% from $35,861,000 in the same period last year[50] - Gross profit margin for the nine months ended February 28, 2025, was 54.4%, compared to 49.9% for the same period in 2024[34] Expenses and Cost Management - Research and development expenses for the three months ended February 28, 2025, were $6,913 thousand, down from $8,189 thousand in the same period last year, reflecting a decrease of 15.6%[32] - Total operating expenses for the nine months ended February 28, 2025, were $149,814 thousand, significantly lower than $348,668 thousand for the same period in 2024[34] - The company incurred acquisition, restructuring, and other items totaling $3,286,000 for the three months ended February 28, 2025, down from $35,367,000 in the same period in 2024[43] - The company reported depreciation and amortization expenses of $6.319 million for the three months ended February 28, 2025, compared to $7.522 million for the same period last year[58] - Stock-based compensation for the three months ended February 28, 2025, was $2,398,000, compared to $2,612,000 for the same period in 2024[37] Cash Flow and Assets - Cash and cash equivalents decreased to $44,760,000 from $76,056,000 in the previous period[56] - Current liabilities were reported at $77,971,000, a decrease from $91,155,000 in the prior period[56] - Cash flows from operating activities resulted in a net cash used of $13.159 million for the three months ended February 28, 2025, compared to $12.526 million for the same period last year[58] - Net cash provided by financing activities was $7.147 million for the three months ended February 28, 2025, compared to $694 thousand for the same period last year[58] - The company had a net cash used in investing activities of $3.189 million for the three months ended February 28, 2025, compared to a net cash provided of $29.404 million for the same period last year[58] - The company reported total assets of $285,415,000 as of February 28, 2025, down from $317,671,000 as of May 31, 2024[56] Strategic Initiatives - The company is focused on strategic initiatives to enhance product development and market expansion, particularly in response to competitive pressures and regulatory challenges[30] - The company initiated the AMBITION BTK RCT to evaluate the Auryon Atherectomy System for treating critical limb ischemia[16] - The NanoKnife System received FDA clearance for prostate tissue ablation, with a pivotal study showing 84% of men free from significant disease at 12 months[18]

Company Overview - AngioDynamics, Inc. (ANGO) has initiated a clinical study named AMBITION BTK to compare the Auryon Atherectomy System combined with standard balloon angioplasty against standard balloon angioplasty alone for treating infrapopliteal lesions in patients with critical limb ischemia below-the-knee [1] - The Auryon Atherectomy System is an advanced laser-based technology designed to treat arterial blockages while minimizing damage to vessel walls, and it is FDA-cleared for treating blockages and in-stent restenosis in the lower limbs [9][10] Clinical Study Details - The AMBITION BTK trial aims to recruit up to 200 participants across 30 hospital-based sites, with a companion registry including up to 1,500 patients treated with the Auryon system who do not qualify for the RCT [5] - This trial builds on the success of a previous study that demonstrated the safety and effectiveness of the Auryon system in treating complex BTK lesions, where 60 patients were treated with excellent clinical results and minimal complications [6][8] Financial Performance - AngioDynamics reported an adjusted loss per share of 4 cents for the second quarter of fiscal 2025, an improvement from a loss of 5 cents in the same quarter the previous year [12] - The company's net sales for the second quarter of fiscal 2025 were $73.0 million, reflecting a 9.2% increase year-over-year, with Med Tech sales rising 25% to $31.5 million, driven by strong performances from the Auryon system and other products [13] Market Position and Growth Potential - AngioDynamics has a market capitalization of $504.2 million and a P/S ratio of 1.76, which is lower than the industry average of 2.83 [4] - The development of the Auryon system is expected to enhance AngioDynamics' position in the growing market for peripheral artery disease treatments, potentially leading to increased sales and market share [3] - The global laser atherectomy devices market is projected to grow from $182.1 million in 2022 to over $345.4 million by 2031, with a CAGR of 7.4%, driven by the rising prevalence of atherosclerosis and demand for minimally invasive procedures [11]

Group 1 - AngioDynamics has a less-than-ideal track record and faces ongoing challenges in its slow-growing legacy operations [1] - Despite these challenges, there is a bullish outlook on AngioDynamics stock due to better results in the growth-oriented Medical Tech segment [1]